Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + Regorafenib in HCC
NCT05770882Phase 2Terminated
- Sponsor
- GNT Biotech & Medicals
- Start
- Apr 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in hepatocellular carcinoma (HCC), sponsored by GNT Biotech & Medicals. Started Apr 2023; status: terminated.
02
Drugs
tucidinostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05770882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05770882.